Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma

Bone Marrow Transplantation volume 37, pages 1037–1042 (2006)Cite this article

Abstract

To understand the prognostic value of lymphocyte recovery after autologous peripheral blood stem cell transplantation (APBSCT), we performed a retrospective study of 59 newly diagnosed multiple myeloma (MM) patients who underwent frontline APBSCT. Conditioning regimens were melphalan 100 mg/m2 for 2 days. Following APBSCT, all patients showed complete or partial response. Median follow-up time was 29.57 months and median recovery of absolute lymphocyte count (ALC) ⩾1000/mm3 was 23 days. Univariate analysis revealed that significant predictors of overall survival (OS) included bone marrow (BM) plasma cells ⩽40% at diagnosis (P=0.0243) and recovery of ALC ⩾1000/mm3 by day +23 (P=0.0156). Positive predictors for progression-free survival (PFS) were BM plasma cells ⩽40% at diagnosis (P=0.0134) and recovery of ALC ⩾1000/mm3 by day +23 (P=0.0243). Absolute neutrophil count ⩾1000/mm3 on day +12 was marginally significant for OS and PFS (P=0.0821 and P=0.1153, respectively). Multivariate analysis showed that ALC ⩾1000/mm3 on day +23 independently predicted OS (P=0.031) and prolonged PFS (P=0.011), and that serum β2-microglobulin was marginally significant for prolonged OS (P=0.066). In conclusion, ALC recovery was an independent predictor of both OS and PFS in MM.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005; 105: 4532–4539.

    Article  CAS  PubMed  Google Scholar 

  2. Vesole DH . Transplantation for multiple myeloma: who, when, how often? Patient selection and goals. Blood 2003; 102: 3471–3472.

    Article  CAS  PubMed  Google Scholar 

  3. Kumar A, Loughran T, Alsina M, Durie BG, Djulbegovic B . Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol 2003; 4: 293–304.

    Article  PubMed  Google Scholar 

  4. Porrata LF, Litzow MR, Markovic SN . Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc 2001; 76: 407–412.

    Article  CAS  PubMed  Google Scholar 

  5. Steingrimsdottir H, Gruber A, Bjorkholm M, Svensson A, Hansson M . Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica 2000; 85: 832–838.

    CAS  PubMed  Google Scholar 

  6. Hernandez MD, del Canizo MC, Gonzalez M, Caballero MD, Lopez-Berges MC, Vazquez L et al. Immune reconstitution after autologous progenitor hemopoietic cell transplantation. A study comparing autologous bone marrow and autologous peripheral blood transplantation. Med Clin (Barc) 1998; 110: 768–773.

    CAS  Google Scholar 

  7. Roberts MM, To LB, Gillis D, Mundy J, Rawling C, Ng K et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 12: 469–475.

    CAS  PubMed  Google Scholar 

  8. Rosillo MC, Ortuno F, Moraleda JM, Lozano ML, Heras I, De Arriba F et al. Immune recovery after autologous or rhG-CSF primed PBSC transplantation. Eur J Haematol 1996; 56: 301–307.

    Article  CAS  PubMed  Google Scholar 

  9. Marin GH, Mendez MC, Menna ME, Malacalza J, Bergna MI, Klein G et al. Immune recovery after bone marrow and peripheral blood stem cells transplantation. Transplant Proc 1999; 31: 2582–2584.

    Article  CAS  PubMed  Google Scholar 

  10. Kim H, Sohn HJ, Kim SE, Kang HJ, Park S, Kim S et al. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 34: 43–49.

    Article  CAS  PubMed  Google Scholar 

  11. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579–585.

    Article  CAS  PubMed  Google Scholar 

  12. Porrata LF, Gertz MA, Litzow MR, Lacy MQ, Dispenzieri A, Inwards DJ et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res 2005; 11: 1210–1218.

    CAS  PubMed  Google Scholar 

  13. Porrata LF, Ingle JN, Litzow MR, Geyer S, Markovic SN . Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant 2001; 28: 865–871.

    Article  CAS  PubMed  Google Scholar 

  14. Porrata LF, Inwards DJ, Micallef IN, Ansell SM, Geyer SM, Markovic SN . Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol 2002; 117: 629–633.

    Article  PubMed  Google Scholar 

  15. Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 291–298.

    Article  CAS  PubMed  Google Scholar 

  16. Porrata LF, Litzow MR, Tefferi A, Letendre L, Kumar S, Geyer SM et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002; 16: 1311–1318.

    Article  CAS  PubMed  Google Scholar 

  17. Schrama JG, Rodenhuis S, De Gast GC . Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant 2003; 31: 141–142.

    Article  CAS  PubMed  Google Scholar 

  18. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ . A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 2003; 122: 441–450.

    Article  PubMed  Google Scholar 

  19. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  20. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50–70: results of a randomized controlled trial. Blood 2004; 104: 3052–3057.

    Article  CAS  PubMed  Google Scholar 

  21. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  PubMed  Google Scholar 

  22. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E et al. Treatment of multiple myeloma. Blood 2004; 103: 20–32.

    Article  CAS  PubMed  Google Scholar 

  23. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008–4010.

    CAS  PubMed  Google Scholar 

  24. Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002; 118: 1041–1047.

    Article  CAS  PubMed  Google Scholar 

  25. Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood 2003; 101: 3849–3856.

    Article  CAS  PubMed  Google Scholar 

  26. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579–1583.

    Article  CAS  PubMed  Google Scholar 

  27. Calasanz MJ, Cigudosa JC, Odero MD, Garcia-Foncillas J, Marin J, Ardanaz MT et al. Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma. Br J Haematol 1997; 98: 418–425.

    Article  CAS  PubMed  Google Scholar 

  28. Chang H, Sloan S, Li D, Zhuang L, Yi QL, Chen CI et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004; 125: 64–68.

    Article  PubMed  Google Scholar 

  29. Lee KH, Choi SJ, Lee JH, Lee JS, Kim WK, Lee KB et al. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica 2005; 90: 939–948.

    PubMed  Google Scholar 

  30. Kim DH, Kim JG, Sohn SK, Sung WJ, Suh JS, Lee KS et al. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol 2004; 125: 217–224.

    Article  PubMed  Google Scholar 

  31. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.

    CAS  PubMed  Google Scholar 

  32. Mohty M, Boiron JM, Damaj G, Michallet AS, Bay JO, Faucher C et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 77–84.

    Article  CAS  PubMed  Google Scholar 

  33. Damiani D, Stocchi R, Masolini P, Michelutti A, Sperotto A, Geromin A et al. Dendritic cell recovery after autologous stem cell transplantation. Bone Marrow Transplant 2002; 30: 261–266.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea

    H Kim

  2. Division of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    H-J Sohn, S Kim, J-S Lee, W-K Kim & C Suh

Authors
  1. H Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H-J Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J-S Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W-K Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Suh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, H., Sohn, HJ., Kim, S. et al. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplant 37, 1037–1042 (2006). https://doi.org/10.1038/sj.bmt.1705373

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705373

Keywords

This article is cited by

Search

Advanced search

Quick links